Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label prime-boost H5N1 AS03-adjuvanted influenza vaccine study in adults
2006-005477-22Phase 2Completed
- Sponsor
- GSK
- Start
- Dec 2006
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) in influenza (2 arms), sponsored by GSK. Primary endpoint: Humoral immune response after booster dose. Started Dec 2006; status: completed.
02
Drugs
prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted)
03
Conditions
influenza
Beyond the preview
Go deeper on 2006-005477-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005477-22.